Global medical device firm Sorin Group has completed enrolment in its Respond CRT, an investigational device exemption (IDE) clinical trial.

The trial will evaluate the safety and effectiveness of the new SonR cardiac resynchronisation therapy (CRT) optimisation system in patients with severe heart failure.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

SonR system features a haemodynamic sensor which evaluates the patient’s left ventricular contractility to automatically optimise the atrioventricular (AV) and interventricular (VV) settings, with the goal of improving the patient’s response to CRT.

In the Respond CRT trial, the company enrolled a total of 1,039 patients in Europe, US and Australia.

During the trial, patients were randomised to receive either SonR weekly automatic optimisation or manual echocardiography optimisation at a pre-discharge visit and are followed in a double-blinded fashion.

See Also:

"In the Respond CRT trial, the company has enrolled a total of 1,039 patients in Europe, US and Australia."

The trial’s primary effectiveness endpoint will be evaluated at the 12 month follow-up and results are expected to be reported in spring 2016.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial is designed to build upon the company’s CLEAR clinical trial which evaluated the SonR CRT optimisation system in 238 European patients.

Results from the CLEAR trial showed that at 12 months 76% of patients receiving SonR CRT optimisation were classified as improved, compared to 62% in the control patient group followed with standard practice.

Sorin Group president CRM business unit Stefano Di Lullo said: "Respond CRT is a key trial to further demonstrate the clinical benefits of our innovative SonR technology.

"After SonR’s successful introduction in Europe, this study serves as a cornerstone to obtain FDA approval and to make this unique solution available to many of the five million Americans suffering from heart failure."

The SonR haemodynamic sensor is designed to measure a patient’s cardiac muscle vibrations, which reflect the left ventricular contractility, a key indicator of cardiac performance.